Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Issue 11 (8th July 2014)

• Record Type: Journal Article
• Authors: Sha, S.; Polidori, D.; Heise, T.; Natarajan, J.; Farrell, K.; Wang, S.‐S.; Sica, D.; Rothenberg, P.; Plum‐Mörschel, L.
• Is Part Of: Diabetes, obesity & metabolism. Volume 16:Issue 11(2014:Nov.)
• Page Start: 1087
• Page End: 1095
• Publication Date: 2014-07-08
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12322
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main" id="dom12322-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="dom12322-sec-0001" sec-type="section"> <title>Aim</title> <p id="dom12322-para-0001">To evaluate the effects of canagliflozin on plasma volume, urinary glucose excretion (UGE), fasting plasma glucose (FPG), glycated haemoglobin (HbA1c) and additional measures of fluid/electrolyte balance in patients with type 2 diabetes on background therapy with metformin and angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers.</p> </sec> <sec id="dom12322-sec-0002" sec-type="section"> <title>Methods</title> <p id="dom12322-para-0002">Patients (<italic>N</italic> = 36) were randomized (1 : 1) to receive canagliflozin 300 mg or placebo for 12 weeks. Pharmacodynamic parameters were assessed at baseline and at weeks 1 and 12.</p> </sec> <sec id="dom12322-sec-0003" sec-type="section"> <title>Results</title> <p id="dom12322-para-0003">Increased 24‐h UGE was seen in the canagliflozin group compared with a reduction in the placebo group at both week 1 (91.8 vs. −2.4 g) and week 12 (82.6 vs. −0.4 g). Canagliflozin also reduced both FPG and HbA1c. Reductions in body weight and blood pressure were observed at weeks 1 and 12. Canagliflozin decreased plasma volume compared with an increase with placebo at week 1 (−5.4 vs. 4.3%; p = 0.02), but this was largely attenuated at week 12 (4.6 vs. 5.8%; p = 0.76). A modest numerical increase in urine volume was observed with canagliflozin at week 1 that was attenuated at week 12; other measures of volume status (i.e. blood urea nitrogen, serum creatinine and haematocrit) remained modestly increased with canagliflozin at week 12.</p> </sec> <sec id="dom12322-sec-0004" sec-type="section"> <title>Conclusion</title> <p id="dom12322-para-0004">Canagliflozin provided sustained effects on UGE and FPG over 12 weeks and a transient reduction in plasma volume that was largely attenuated by week 12.</p> </sec> </abstract>